Analyst thinks RSV vaccine market could reach over USD 10bn

Glaxosmithkline, Johnson & Johnson and Pfizer are likely to win big on the sale of RSV vaccines, but Bavarian Nordic could also profit nicely off the billion-dollar market, analyst at investment bank Leerink assesses.

Even if Bavarian Nordic is a great deal behind others in the development of RSV vaccine, it could still profit off the billion-dollar market | Photo: Bavarian Nordic / PR

As companies move closer to completing a vaccine against the respiratory syncytial virus, a potentially very lucrative new market begins to emerge. It could even reach a size of USD 10.5bn in the next decade, estimates analyst at SVB Leerink Geoffrey Porges, according to Fiercepharma.

He thinks the well-established vaccine producers Glaxosmithkline, Pfizer and Johnson & Johnson will run with the biggest market share – respectively of USD 2.9bn, USD 2.1bn and USD 1.7bn by 2030.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs